Adjuvant Nivolumab or Ipilimumab + Nivolumab Determined by Pathological Response to a Single Dose of Neoadjuvant Nivolumab
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
University of Pennsylvania
Start Date
December 8, 2021
End Date
September 17, 2026
Administered By
Duke Cancer Institute
Awarded By
University of Pennsylvania
Start Date
December 8, 2021
End Date
September 17, 2026